Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction.

abstract：:Healthcare professionals (e.g., physicians, physician assistants, pharmacists, nurses and genetic counselors) believe pharmacogenomics (PGx) is essential to personalized medicine; however, they still lack confidence prescribing, dosing, interacting with other healthcare professionals and counseling patients with regar...

journal_title：Pharmacogenomics

authors： Nickola TJ,Green JS,Harralson AF,O'Brien TJ

更新日期：2012-09-01 00:00:00

abstract：:Comprehensive, systematic and integrated data-centric statistical approaches to disease modeling can provide powerful frameworks for understanding disease etiology. Here, one such computational framework based on redescription mining in both its incarnations, static and dynamic, is discussed. The static framework prov...

journal_title：Pharmacogenomics

authors： Waltman P,Pearlman A,Mishra B

更新日期：2006-04-01 00:00:00

abstract：:A DNA microarray system is usually comprised of DNA probes formatted on a microscale on a glass surface (chip), plus the instruments needed to handle samples (automated robotics), to read the reporter molecules (scanners) and analyse the data (bioinformatic tools). Biochips are formed by in situ (on chip) synthesis of...

journal_title：Pharmacogenomics

authors： Jain KK

更新日期：2000-08-01 00:00:00

abstract：OBJECTIVE:We designed this trial to investigate if modifications in levels of circulating vascular endothelial growth factor (VEGF) may be related to clinical response and outcome in advanced colorectal cancer patients during treatment with a weekly combination of cetuximab plus irinotecan. METHODS:A total of 45 heavi...

journal_title：Pharmacogenomics

authors： Vincenzi B,Santini D,Russo A,Gavasci M,Battistoni F,Dicuonzo G,Rocci L,Rosaria VM,Gebbia N,Tonini G

更新日期：2007-04-01 00:00:00

abstract：:This review will summarize the role of pharmacogenetics in the natural history of hepatitis C, particularly in patients with HIV/HCV and will take the perspective of pharmacogenetics and its influence on the response to antiviral therapy and the susceptibility to develop adverse effects. This review will also devote a...

journal_title：Pharmacogenomics

authors： Frias M,Rivero-Juárez A,López-López P,Rivero A

更新日期：2018-08-01 00:00:00

abstract：:Genetic variation in the beta 2-adrenoceptor and its associated proteins is common and therefore potentially relevant to the clinician. Several functional SNPs have been described but in vitro studies have yielded inconsistent results. Confounding due to the variable presence of other polymorphic alleles may be the ex...

journal_title：Pharmacogenomics

authors： Taylor DR,Kennedy MA

更新日期：2002-03-01 00:00:00

abstract：AIMS:Bipolar disorder (BD) is a lifelong psychiatric illness characterized by manic and depressive episodes affecting 1-5% of the general population. Among mood-stabilizing treatments, lithium represents the mainstay in the therapeutic management of BD. However, besides the relatively high rate of excellent responders,...

journal_title：Pharmacogenomics

authors： Squassina A,Manchia M,Borg J,Congiu D,Costa M,Georgitsi M,Chillotti C,Ardau R,Mitropoulos K,Severino G,Del Zompo M,Patrinos GP

更新日期：2011-11-01 00:00:00

abstract：:The pharmacokinetic and pharmacodynamic disciplines address pharmacological traits, including efficacy and adverse events. Pharmacogenomics studies have identified pervasive genetic effects on treatment outcomes, resulting in the development of genetic biomarkers for optimization of drug therapy. Pharmacogenomics-base...

journal_title：Pharmacogenomics

authors： Chhibber A,Kroetz DL,Tantisira KG,McGeachie M,Cheng C,Plenge R,Stahl E,Sadee W,Ritchie MD,Pendergrass SA

更新日期：2014-12-01 00:00:00

abstract：OBJECTIVES:In an attempt to elucidate the relationship between biomarkers of tumor hypoxia, glycolysis and angiogenesis, we tested the hypothesis that intratumoral gene expression of the hypoxia response (hypoxia inducible factor [HIF1 alpha and 2 alpha]), glycolysis (lactate dehydrogenase A [LDHA]), glucose metabolism...

journal_title：Pharmacogenomics

authors： Azuma M,Shi M,Danenberg KD,Gardner H,Barrett C,Jacques CJ,Sherod A,Iqbal S,El-Khoueiry A,Yang D,Zhang W,Danenberg PV,Lenz HJ

更新日期：2007-12-01 00:00:00

abstract：:Genome-wide association studies (GWAS) allow the finding of genetic variants associated with several traits. Regarding ovarian cancer (OC), 15 GWAS have been conducted since 2009, with the discovery of 49 SNPs associated with disease susceptibility and 46 with impact in the clinical outcome of patients (p < 5.00 × 10-...

journal_title：Pharmacogenomics

authors： Pinto R,Assis J,Nogueira A,Pereira C,Pereira D,Medeiros R

更新日期：2017-11-01 00:00:00

abstract：:PON1 is a key component of high-density lipoproteins (HDLs) and is at least partially responsible for HDL's antioxidant/atheroprotective properties. PON1 is also associated with numerous human diseases, including cardiovascular disease, Parkinson's disease and cancer. In addition, PON1 metabolizes a broad variety of s...

journal_title：Pharmacogenomics

authors： Kim DS,Marsillach J,Furlong CE,Jarvik GP

更新日期：2013-09-01 00:00:00

abstract：:The completion of the first draft of the human genome sequence has revived the old notion that there is no one-to-one mapping between genotype and phenotype. It is now becoming clear that to elucidate the fundamental principles that govern how genomic information translates into organismal complexity, we must overcome...

journal_title：Pharmacogenomics

authors： Huang S

更新日期：2001-08-01 00:00:00

abstract：AIMS:Survivin (SVV) mRNA expression levels in peripheral blood of patients with gastrointestinal malignancies change significantly during the course of treatment. We wanted to scrutinize these findings in patients with esophageal carcinoma and furthermore evaluate whether the detection of mRNA and the change in detecti...

journal_title：Pharmacogenomics

authors： Hoffmann AC,Vallböhmer D,Grimminger P,Metzger R,Prenzel KL,Hoelscher AH,Brabender J

更新日期：2010-03-01 00:00:00

abstract：:The most prescribed medication for controlling bronchoconstriction associated with asthma and chronic obstructive pulmonary disease are beta-agonists. The gene ADRbeta2 encodes the beta-2-adrenergic receptor and contains several common genetic variations that affect gene expression and receptor function in vitro. The ...

journal_title：Pharmacogenomics

authors： Hawkins GA,Weiss ST,Bleecker ER

更新日期：2008-03-01 00:00:00

abstract：AIMS:Individuals with both diabetes mellitus (DM) and the Haptoglobin (Hp) 2-2 genotype are at increased risk of cardiovascular disease. As the antioxidant function of the Hp 2-2 protein is impaired, we sought to test the pharmacogenomic hypothesis that antioxidant vitamin E supplementation would provide cardiovascular...

journal_title：Pharmacogenomics

authors： Blum S,Vardi M,Brown JB,Russell A,Milman U,Shapira C,Levy NS,Miller-Lotan R,Asleh R,Levy AP

更新日期：2010-05-01 00:00:00

abstract：:Many biomarkers indicate prognosis in chronic lymphocytic leukemia; such as fluorescence in situ hybridization testing: 17p or 11q deletions have a worse prognosis than trisomy 12, 13q deletion or normal result, or the mutational status of the immunoglobulin heavy chain (IGHV): unmutated IGHV have a worse prognosis th...

journal_title：Pharmacogenomics

authors： Hobeika C,Rached G,Chebly A,Chouery E,Kourie HR

更新日期：2020-08-01 00:00:00

abstract：AIM:We conducted a genome-wide association study using the Illumina Exome Array to identify coding SNPs that may explain additional warfarin dose variability. PATIENTS & METHODS:Analysis was performed after adjustment for clinical variables and genetic factors known to influence warfarin dose among 1680 warfarin users...

journal_title：Pharmacogenomics

authors： Liu N,Irvin MR,Zhi D,Patki A,Beasley TM,Nickerson DA,Hill CE,Chen J,Kimmel SE,Limdi NA

更新日期：2017-07-01 00:00:00

abstract：AIM:Cytidine deaminase (CDA) irreversibly deaminates cytarabine (Ara-C), a key component of acute myeloid leukemia (AML) induction and consolidation therapy. CDA overexpression results in Ara-C resistance, while decreased expression is associated with toxicity. We evaluated factors influencing variation in CDA mRNA exp...

journal_title：Pharmacogenomics

authors： Abraham A,Varatharajan S,Abbas S,Zhang W,Shaji RV,Ahmed R,Abraham A,George B,Srivastava A,Chandy M,Mathews V,Balasubramanian P

更新日期：2012-02-01 00:00:00

abstract：:Atrial fibrillation (AF) is most common arrhythmia in general population, with increasing trend in mortality and morbidity. Electrophysiological and structural abnormalities, promoting abnormal impulse formation and propagation, lead to this disease. AF catheter ablation is related to a not small percentage of nonresp...

journal_title：Pharmacogenomics

authors： Sardu C,Santamaria M,Paolisso G,Marfella R

更新日期：2015-11-01 00:00:00

abstract：INTRODUCTION:Most cancer pharmacogenetic studies use germline DNA, as tumor tissue is often inaccessible in the advanced disease setting. However, this relies on the assumption that germline DNA is representative of the tumor genotype. To date, there has been little attention paid to defining the relationship between t...

journal_title：Pharmacogenomics

authors： Marsh S,Mallon MA,Goodfellow P,McLeod HL

更新日期：2005-12-01 00:00:00

abstract：:Despite their clearly distinct pathophysiologies, HIV and cancer are diseases whose response to chemotherapy treatment varies substantially amongst patients, in particular for those with prior drug exposure. This has been attributed, in part, to elevated expression of the ABCB1 drug transporter in some patients, which...

journal_title：Pharmacogenomics

authors： Reed K,Parissenti AM

更新日期：2011-10-01 00:00:00

abstract：:The efficiency of new generation sequencing methods and the reduction of their cost has led pharmacogenomics to gradually supplant pharmacogenetics, leading to new applications in personalized medicine along with new perspectives in drug design or identification of drug response factors. The amount of data generated i...

journal_title：Pharmacogenomics

authors： Barrot CC,Woillard JB,Picard N

更新日期：2019-06-01 00:00:00

abstract：:High-throughput data collection using gene microarrays has great potential as a method for addressing the pharmacogenomics of complex biological systems. Similarly, mechanism-based pharmacokinetic/pharmacodynamic modeling provides a tool for formulating quantitative testable hypotheses concerning the responses of comp...

journal_title：Pharmacogenomics

authors： Almon RR,DuBois DC,Piel WH,Jusko WJ

更新日期：2004-07-01 00:00:00

abstract：AIMS:The importance of polymorphisms in the dihydropyrimidine dehydrogenase gene (DPYD) for the prediction of severe toxicity in 5-fluorouracil (5-FU)-based chemotherapy is still unclear. This study aims to assess the predictive value of DPYD variation with respect to previously described DPYD variants for 5-FU toxicit...

journal_title：Pharmacogenomics

authors： Amstutz U,Farese S,Aebi S,Largiadèr CR

更新日期：2009-06-01 00:00:00

abstract：AIM:CYP2C9 is one of the major drug metabolizing enzymes, however, little is known about polymorphisms in CYP2C9 gene and pharmacological implications in Mexican indigenous populations. Thus, frequencies of CYP2C9*2 and CYP2C9*3 alleles were evaluated in indigenous groups located in northwest (Cora), center (Mazahua an...

journal_title：Pharmacogenomics

authors： Sánchez-Pozos K,Rivera-Santiago C,García-Rodríguez MH,Ortiz-López MG,Peña-Espinoza BI,Granados-Silvestre MLÁ,Llerena A,Menjívar M

更新日期：2016-11-01 00:00:00

abstract：:The advent of genome-wide association studies has allowed considerable progress in the identification and robust replication of common gene variants that confer susceptibility to common diseases and other phenotypes of interest. These genetic effect sizes are almost invariably moderate to small in magnitude and single...

journal_title：Pharmacogenomics

authors： Zeggini E,Ioannidis JP

更新日期：2009-02-01 00:00:00

abstract：:Aim: We investigated if DEPTOR polymorphisms influence metabolic parameters and risk for vascular complications in Type 2 diabetes (T2D) patients. Methods: T2D patients were genotyped for DEPTOR rs7840156, rs2271900 and rs4871827. We built low homology model of DEPTOR to check the position of two investigated substitu...

journal_title：Pharmacogenomics

authors： Klen J,Goričar K,Horvat S,Stojan J,Dolžan V

更新日期：2019-08-01 00:00:00

abstract：:The human µ-opioid receptor variant 118 A>G (rs1799971) has become one of the most analyzed genetic variants in the pain field. At the molecular level, the variant reduces opioid receptor signaling efficiency and expression, the latter probably via a genetic-epigenetic interaction. In experimental settings, the varian...

journal_title：Pharmacogenomics

authors： Walter C,Doehring A,Oertel BG,Lötsch J

更新日期：2013-11-01 00:00:00

abstract：AIM:Gemcitabine is the first chemotherapeutic agent to show clinical benefits in pancreatic cancer patients. While interindividual variability in chemoresponse is observed, genetic factors that affect drug metabolism have not been clearly defined. The purpose of this study is to evaluate the relationships between genet...

journal_title：Pharmacogenomics

authors： Woo HI,Kim KK,Choi H,Kim S,Jang KT,Yi JH,Park YS,Park JO,Lee SY

更新日期：2012-07-01 00:00:00

abstract：:Drug-induced liver injury (DILI) is an increasing health problem and a challenge for physicians, regulatory bodies and the pharmaceutical industry, not only because of its potential severity and elusive pathogenesis but also because it is often inaccurately diagnosed, commonly missed entirely and more often not report...

journal_title：Pharmacogenomics

authors： Andrade RJ,Robles M,Ulzurrun E,Lucena MI

更新日期：2009-09-01 00:00:00